Search - tctmd.com

Displaying 1 - 20 of 72

Sort: Relevancy | Date

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #3: Novel Tips and Tricks to Simplify TAVI

Presenter: Fabian Nietlispach

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #2: Economic Benefits With a Minimalist TAVR Strategy Are Indisputable!

Presenter: Hemal Gada

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #1: Preserving TEE is Fundamental Results From a High-Volume Minimalist TAVR Center

Presenter: Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Voice of Interventional Echocardiography: Situations where TEE Provides Meaningful Value During TAVR (With Convincing Case Examples)

Presenter: Vinod H. Thourani, John G. Webb, Rebecca T. Hahn

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Vancouver Minimalist Clinical Care Pathway: Updates from the 3M Trial and Evolution to BENCHMARK

Presenter: Vinod H. Thourani, John G. Webb, David A. Wood

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Minimalist TAVR Strategy Should be the Default Approach Supported by Clinical Outcomes and Economic Benefits

Presenter: Vinod H. Thourani, John G. Webb

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Raj Makkar

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Raj Makkar, Maria Alu, MS

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Raj Makkar, Lars Sondergaard

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

Presenter: Howard C. Herrmann, Allan Schwartz, Eberhard Grube

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Presenter: Howard C. Herrmann, Allan Schwartz, Jonathan Afilalo

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

Presenter: Howard C. Herrmann, Allan Schwartz, Suzanne V. Arnold

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

CLINICAL VIEWPOINT: Problems With the Current Practice of Watchful Waiting in Managing Asymptomatic Patients With Severe AS

Presenter: Howard C. Herrmann, Allan Schwartz

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: Howard C. Herrmann, Allan Schwartz, Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: Howard C. Herrmann, Allan Schwartz, Nicolas M. Van Mieghem

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

A Clinical Algorithm for Diagnosing and Managing Patients With Low-Flow, Low-Gradient Aortic Stenosis

Presenter: Howard C. Herrmann, Allan Schwartz

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

CASE #5 New York City (Columbia)

Presenter: Tamim Nazif

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

CASE #4 Zurich, Switzerland

Presenter: Francesco Maisano

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

CASE #3 Laval, Canada

Presenter: Josep Rodés-Cabau

June 22, 2018

Advertisement

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Snapshot #3: Novel Tips and Tricks to Simplify TAVI

Snapshot #2: Economic Benefits With a Minimalist TAVR Strategy Are Indisputable!

Snapshot #1: Preserving TEE is Fundamental Results From a High-Volume Minimalist TAVR Center

The Voice of Interventional Echocardiography: Situations where TEE Provides Meaningful Value During TAVR (With Convincing Case Examples)

The Vancouver Minimalist Clinical Care Pathway: Updates from the 3M Trial and Evolution to BENCHMARK

The Minimalist TAVR Strategy Should be the Default Approach Supported by Clinical Outcomes and Economic Benefits

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

CLINICAL VIEWPOINT: Problems With the Current Practice of Watchful Waiting in Managing Asymptomatic Patients With Severe AS

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Clinical Algorithm for Diagnosing and Managing Patients With Low-Flow, Low-Gradient Aortic Stenosis

CASE #5 New York City (Columbia)

CASE #4 Zurich, Switzerland

CASE #3 Laval, Canada

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content